Moss, 15 May 2018
Gentian Diagnostics AS announces its results for the first quarter of 2018. The highlights include
- Record level for total operating revenue of MNOK 11.2 for the quarter
- 100 % growth in sales revenue compared to 1Q17
- 24 % growth in sales revenue compared to 4Q17
- Strong sales for both Cystatin C and fCal
- New Proof-of-Concept announced post end of quarter
Please find the report enclosed. The report will also be made available on www.gentian.com.
For further information, please contact:
MeldingsID: 451378
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL